Welcome to Bull Street Buzz — Wednesday, August 13th 2025, 5:10am — Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease - Novartis — Swiss sneaker company On beats sales estimates, raises guidance despite Vietnam tariffs - CNBC — The great "rebalancing" in EV lithium has begun - Axios
About Us Disclaimer The Bull Street Portfolio Sign Stock Search (beta) The Bull Street IRA
Total Visitors: 3080 | Last 7 Days: 387 | Last 24 Hours: 61
Last Access: Wednesday, August 13th 2025, 4:36am | Last IP: 216.73.216.187